HOMA-IR: How to Interpret Your Insulin Resistance Score (Australia Guide)

Learn how to calculate and interpret your HOMA-IR score from fasting glucose and insulin. Understand optimal vs at-risk ranges, how to get tested in Australia, and what drives high insulin resistance.

Fasting glucose sits comfortably in the normal range for millions of Australians — and yet insulin resistance has already taken hold beneath the surface. The reason is straightforward: glucose is a lagging indicator. By the time fasting blood sugar rises, the pancreas has typically been overcompensating with excess insulin for years.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) was developed to catch this earlier. By pairing fasting insulin with fasting glucose, it quantifies how hard the body is working to maintain normal blood sugar — revealing metabolic dysfunction that a glucose test alone will miss. This guide covers what the number means, how to calculate it, what it looks like in an Australian testing context, and what to do if yours is elevated.

What HOMA-IR Actually Measures

HOMA-IR is a mathematical model developed in the 1980s by Matthews and colleagues at Oxford. It estimates the degree of insulin resistance based on the relationship between two fasting values: your blood insulin level and your blood glucose level.

In a person with healthy insulin sensitivity, a small amount of insulin is sufficient to keep blood glucose stable overnight. In someone developing insulin resistance, the pancreatic beta cells must secrete progressively more insulin to achieve the same effect. HOMA-IR captures this by placing fasting insulin in the numerator — higher insulin relative to glucose signals greater resistance.

The model assumes that in a healthy, non-diabetic person, the insulin-glucose feedback loop operates at a predictable baseline. Deviations from that baseline reflect either increased hepatic glucose output, reduced peripheral glucose uptake, or both — the two hallmarks of insulin resistance.

The HOMA-IR Formula

There are two versions of the formula depending on which unit system your lab uses.

SI units (mmol/L for glucose — standard in Australia):

HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mmol/L]) ÷ 22.5

US units (mg/dL for glucose):

HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mg/dL]) ÷ 405

Australian labs report glucose in mmol/L, so the 22.5 divisor is the one to use locally.

Worked Example

Suppose your fasting results come back as:

Fasting insulin: 8 µIU/mL
Fasting glucose: 5.2 mmol/L

HOMA-IR = (8 × 5.2) ÷ 22.5 = 41.6 ÷ 22.5 = 1.85

That score falls in the early insulin resistance range — worth addressing through lifestyle, but not yet at a level that typically triggers clinical intervention.

Now consider a second scenario:

Fasting insulin: 18 µIU/mL
Fasting glucose: 5.8 mmol/L

HOMA-IR = (18 × 5.8) ÷ 22.5 = 104.4 ÷ 22.5 = 4.64

Despite fasting glucose still sitting within the conventional reference range (<6.0 mmol/L), this HOMA-IR reflects significant metabolic dysfunction requiring action.

HOMA-IR Reference Ranges

Research populations vary, so cut-off values differ slightly between studies. The following ranges are consistent with published functional medicine and clinical research literature and represent a useful working framework.

| HOMA-IR Score | Interpretation | |---|---| | <1.0 | Optimal insulin sensitivity | | 1.0 – 1.9 | Early / mild insulin resistance | | 2.0 – 2.9 | Significant insulin resistance | | >2.9 | Strong insulin resistance |

A HOMA-IR below 1.0 reflects robust insulin sensitivity — the metabolic state associated with lowest risk of type 2 diabetes, cardiovascular disease, and NAFLD. A score above 2.9 is associated with substantially elevated risk across all major metabolic conditions and should trigger both lifestyle intervention and further clinical investigation.

It is worth noting that HOMA-IR was validated primarily in non-diabetic, non-obese populations. In individuals already using insulin therapy, the model is not applicable. Similarly, results should be interpreted in context — ethnicity, age, and body composition can all influence where an individual's baseline sits.

Why Fasting Glucose Alone Is Not Enough

Standard metabolic panels routinely measure fasting glucose. Fasting insulin is ordered far less often — which creates a significant blind spot.

Consider the progression of insulin resistance:

Insulin sensitivity begins to decline at the tissue level (muscle, liver, fat cells).
The pancreas compensates by secreting more insulin — blood glucose remains normal.
This compensated phase can persist for a decade or more before glucose rises.
Eventually, beta cell capacity is exhausted and glucose begins to climb.

A fasting glucose test performed during stage 2 or 3 will return a completely normal result, giving false reassurance. The person has insulin resistance — they just have a pancreas that is working overtime to hide it.

Adding fasting insulin to the picture exposes the compensation. A fasting insulin of 15 µIU/mL with a normal glucose is diagnostic of significant resistance even before glucose dysregulation appears. This is precisely why functional medicine practitioners consistently argue that fasting insulin is one of the most underutilised tests in preventive medicine.

As discussed in our guide on how to interpret blood test results, understanding the difference between "within reference range" and "optimal" is central to getting genuine value from blood testing.

Getting Tested in Australia: The Medicare Rebate Gap

Here is where Australian patients run into a practical obstacle.

Fasting glucose is Medicare-rebated as part of a standard metabolic panel when ordered by a GP. It is inexpensive and widely available.

Fasting insulin is a different story. Medicare does not routinely rebate fasting insulin testing unless specific clinical criteria are met — typically relating to hypoglycaemia investigation or insulin antibody assessment rather than metabolic screening. A GP ordering fasting insulin for the purpose of calculating HOMA-IR in an otherwise healthy patient will generally not be able to apply a Medicare item number.

This means most Australians seeking a HOMA-IR calculation will need to access fasting insulin through:

Private pathology testing — Direct-to-consumer options allow you to order fasting insulin without a GP referral. Costs typically range from $40–$80 for insulin, and fasting glucose is usually bundled cheaply or already known. Our private blood test Australia guide covers the available services, pricing, and what to expect from the process.
Integrative or functional medicine practitioners — These practitioners routinely order fasting insulin as part of metabolic panels and can provide clinical context for results. A consultation typically includes the cost of pathology.
Sports medicine or endocrinology referrals — If a GP suspects metabolic syndrome or pre-diabetes, a specialist referral may unlock broader testing with rebate coverage.

The practical upshot: plan for out-of-pocket costs unless you have an existing metabolic diagnosis. Given that HOMA-IR can identify insulin resistance a decade before conventional markers become abnormal, most people who get it tested consider the investment worthwhile.

Clinical Significance: What High HOMA-IR Predicts

Elevated HOMA-IR is not merely a number — it is one of the most robust surrogate markers of systemic metabolic dysfunction available outside a formal glucose tolerance test. The conditions it tracks risk for include:

Non-alcoholic fatty liver disease (NAFLD). Insulin resistance drives excess hepatic lipogenesis. HOMA-IR correlates closely with liver fat accumulation and is used in several NAFLD risk scoring systems. Elevated HOMA-IR often precedes abnormal liver enzymes on a standard panel.

Polycystic ovarian syndrome (PCOS). Insulin resistance is a core driver of PCOS pathophysiology in the majority of affected women, amplifying LH secretion and androgen production. HOMA-IR is frequently elevated even in lean women with PCOS — making it a critical marker to test in this population.

Type 2 diabetes risk. Longitudinal data consistently shows that HOMA-IR in the pre-diabetic range predicts conversion to type 2 diabetes with greater sensitivity than fasting glucose alone. The insulin-resistant state can persist for 10–15 years before HbA1c moves.

Cardiovascular disease. Insulin resistance drives atherogenic dyslipidaemia — characteristically elevated triglycerides, low HDL, and small dense LDL particles. High HOMA-IR is independently associated with coronary artery disease risk and is mechanistically linked to endothelial dysfunction and systemic inflammation.

Metabolic syndrome. HOMA-IR sits at the centre of metabolic syndrome pathophysiology. All five diagnostic criteria (elevated waist circumference, high triglycerides, low HDL, high blood pressure, elevated fasting glucose) are worsened by insulin resistance.

For men, the connection extends further. Insulin resistance suppresses sex hormone-binding globulin (SHBG), reduces free testosterone, and contributes to hypogonadism. Our breakdown of optimal testosterone ranges for men discusses this metabolic-hormonal axis in more detail.

What Drives High HOMA-IR

Insulin resistance does not emerge from a single cause. It is the product of converging lifestyle, dietary, and physiological factors — most of which are modifiable.

Visceral adiposity. Excess fat stored around the organs — rather than subcutaneous fat — is the primary driver of hepatic and peripheral insulin resistance. Waist circumference is a useful proxy: risk increases significantly above 94 cm in men and 80 cm in women.

Physical inactivity. Skeletal muscle is the largest site of glucose disposal in the body. Inactivity reduces GLUT4 transporter expression and mitochondrial capacity, impeding glucose uptake independent of body weight. Even short bouts of post-meal walking meaningfully improve postprandial glucose and insulin dynamics.

Sleep deprivation. A single night of significantly disrupted sleep reduces insulin sensitivity measurably. Chronic short sleep (<6 hours) is associated with HOMA-IR scores 20–30% higher than matched controls sleeping 7–8 hours. The mechanism involves cortisol dysregulation, growth hormone suppression, and increased hunger hormone activity.

Cortisol and chronic stress. Cortisol is a counter-regulatory hormone that raises blood glucose and suppresses insulin signalling. Chronically elevated cortisol — from psychological stress, HPA axis dysregulation, or exogenous glucocorticoid use — directly elevates HOMA-IR. The cortisol and DHEA adrenal panel is worth considering alongside HOMA-IR in patients with suspected HPA involvement.

High refined carbohydrate intake. Diets dominated by rapidly digestible carbohydrates (refined grains, added sugars, ultra-processed foods) drive chronically elevated postprandial insulin, progressive beta cell stress, and downregulation of insulin receptors. Fructose in particular promotes hepatic insulin resistance and triglyceride synthesis.

Gut microbiome disruption. Emerging evidence links dysbiosis with insulin resistance through several pathways including increased intestinal permeability, endotoxaemia (LPS translocation), and altered short-chain fatty acid production. This is an area of active research rather than settled clinical practice.

How to Improve HOMA-IR

The good news: insulin resistance is one of the most responsive metabolic conditions to lifestyle intervention. Meaningful improvements in HOMA-IR are achievable within weeks of sustained behavioural change.

Resistance training. Lifting weights increases GLUT4 transporter density in muscle tissue and improves insulin-stimulated glucose uptake for 24–48 hours after each session. Studies consistently show resistance training produces larger improvements in HOMA-IR than aerobic exercise alone, though combining both is optimal.

Post-meal walks. Even 10–15 minutes of light walking after meals blunts the postprandial glucose and insulin spike. This is one of the highest-leverage, lowest-barrier interventions available — particularly for desk-based workers.

Dietary carbohydrate quality. Replacing refined carbohydrates with fibre-rich, low-glycaemic alternatives (vegetables, legumes, whole intact grains) reduces the insulin load of meals. Time-restricted eating and lower overall carbohydrate intake (not necessarily ketogenic) consistently improve HOMA-IR in randomised trials.

Specific foods with mechanistic support:

Vinegar (acetic acid) consumed with meals reduces postprandial glucose and insulin
Berberine activates AMPK and has been shown to improve HOMA-IR comparably to metformin in some studies
Omega-3 fatty acids reduce hepatic lipogenesis and improve insulin receptor signalling
Magnesium is a cofactor for over 300 enzymatic reactions including those in insulin signalling cascades; deficiency worsens insulin resistance

Sleep optimisation. Prioritising 7–9 hours of quality sleep has measurable effects on fasting insulin within 1–2 weeks.

Stress management. Interventions that reduce cortisol output — including progressive muscle relaxation, mindfulness, aerobic exercise, and adequate rest — indirectly improve insulin sensitivity.

HOMA-IR in Context: Related Metabolic Markers

HOMA-IR does not exist in isolation. It should be interpreted alongside other markers that collectively paint the metabolic picture.

Triglycerides. Elevated triglycerides (particularly above 1.7 mmol/L, with optimal below 1.0 mmol/L) directly reflect insulin-driven hepatic overproduction of VLDL. The triglyceride-to-HDL ratio is a useful free surrogate for insulin resistance when fasting insulin is not available.

HDL cholesterol. Low HDL (<1.0 mmol/L in men, <1.3 mmol/L in women) frequently accompanies insulin resistance as part of the atherogenic lipid triad. Our CBC blood test optimal ranges guide covers metabolic markers in detail.

Waist circumference. The most accessible clinical measure of visceral adiposity and an independent predictor of insulin resistance. Track alongside HOMA-IR to assess whether body composition improvements are tracking with metabolic improvement.

HbA1c. Reflects average blood glucose over 8–12 weeks. HbA1c tends to remain normal until insulin resistance is advanced — it is a lagging indicator. HOMA-IR will typically be elevated for years before HbA1c moves above 5.7%.

Fasting insulin alone. Some clinicians use fasting insulin as a simpler surrogate without calculating HOMA-IR. A fasting insulin above 12 µIU/mL is generally considered elevated in the functional medicine literature, with optimal values sitting below 8 µIU/mL. This requires only a single number rather than the glucose-insulin ratio, but loses some precision in patients with glucose abnormalities.

HOMA-IR vs Alternative Measures

HOMA-IR is not the only tool for assessing insulin resistance. Understanding where it fits relative to alternatives helps with test selection.

QUICKI (Quantitative Insulin Sensitivity Check Index). A logarithmic transformation of the same fasting insulin and glucose values used in HOMA-IR: 1 / (log fasting insulin + log fasting glucose). QUICKI correlates well with HOMA-IR and some studies suggest slightly better performance at the extremes of insulin resistance. It is rarely used in clinical practice because HOMA-IR is more intuitive to interpret.

Fasting insulin alone. Faster, cheaper, and interpretable without a simultaneous glucose measurement. Useful as a screening marker and for serial monitoring. Less precise than HOMA-IR in patients with borderline glucose.

Oral glucose tolerance test (OGTT) with insulin. The gold standard for capturing the full insulin response — measuring glucose and insulin at multiple time points (fasting, 30 min, 60 min, 120 min) after a 75 g glucose load. Reveals reactive hypoglycaemia, delayed insulin responses, and postprandial insulin excess that fasting-only tests miss entirely. More time-consuming and expensive, but provides the most complete picture of insulin dynamics.

Hyperinsulinaemic-euglycaemic clamp. The research gold standard for insulin resistance measurement — not available in clinical practice.

For most Australians doing metabolic health monitoring, HOMA-IR is the practical first step: it requires only a fasting blood draw, provides an actionable number, and can be retested to track response to intervention. Those interested in the emerging role of peptides in metabolic health — including incretin-based approaches to improving insulin sensitivity — can find relevant metabolic peptide research at OzPeps.

FAQ

Can I calculate HOMA-IR from a standard blood test my GP ordered?

Only if fasting insulin was included in the panel. Most standard GP panels include fasting glucose but not fasting insulin. Check your results report — if insulin is not listed, you will need to arrange a separate fasting insulin test. Private pathology is the most straightforward route for most Australians.

What time of day should I take the test?

Both fasting glucose and fasting insulin must be measured after a minimum 8–12 hour fast (overnight fasting is ideal). Morning tests are standard. Avoid exercising intensely the night before, as this can temporarily suppress fasting insulin and produce an artificially low HOMA-IR result.

My fasting glucose is normal but my HOMA-IR is high — is that possible?

Yes, and this is precisely the scenario HOMA-IR was designed to detect. A high fasting insulin with normal fasting glucose produces an elevated HOMA-IR and indicates compensated insulin resistance — the pancreas is working overtime to hold glucose in the normal range. This can persist for years before glucose rises.

How often should I retest HOMA-IR?

When actively working to improve insulin sensitivity through dietary or lifestyle intervention, retesting every 3 months provides a useful feedback loop. For baseline monitoring in a healthy individual, annual testing alongside a standard metabolic panel is sufficient. Retest after any significant changes in weight, diet, or physical activity.

Is HOMA-IR useful for women with PCOS?

Yes — HOMA-IR is particularly valuable in PCOS because insulin resistance plays a central role in the condition's pathophysiology, yet many women with PCOS have normal fasting glucose. Testing HOMA-IR (alongside fasting insulin, androgens, and LH/FSH) gives a more complete picture than glucose alone and can guide decisions about insulin-sensitising interventions. Some clinicians also recommend the OGTT with insulin in PCOS to capture postprandial insulin patterns.

This article is for informational and educational purposes only. It does not constitute medical advice and should not be used to diagnose or treat any health condition. Consult your GP, endocrinologist, or qualified healthcare practitioner before making any changes to your testing, diet, supplementation, or treatment approach.